Cerus Corp (CU2.DU)
| Previous close | 1.5520 |
| Open | 1.5580 |
| Bid | 1.5570 x N/A |
| Ask | 1.6040 x N/A |
| Day's range | 1.5580 - 1.5580 |
| 52-week range | 1.1355 - 2.7680 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 31 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireCerus Corporation Announces Appointment of Dean Gregory to Board of Directors
CONCORD, Calif., July 02, 2024--Cerus Corporation (Nasdaq: CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain and manufacturing. For the last decade, Mr. Gregory served as President, Global Commercial Operations, Med Tech for Fresenius Kabi, the role from which he retired earlier th
Business WireCerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood Transfusion
CONCORD, Calif., June 21, 2024--Cerus Corporation (Nasdaq:CERS) today announced a lunch symposium and selection of abstracts at the 38th International Congress of the International Society of Blood Transfusion (ISBT), taking place in Barcelona, Spain, from June 23 through June 27. Transfusion medicine experts and professionals from around the world attend the ISBT Congress.
Simply Wall St.Cerus (NASDAQ:CERS) shareholders have endured a 70% loss from investing in the stock three years ago
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...
